Crystallization technologies are bridges between drug substances (DS) and drug products (DP) enabling consistent and robust safety and efficacy profiles for small molecule-based medicines. In effort to fully utilize existing tools and develop better methodologies for solving bottleneck problems in new drug development programs, the annual Pharmaceutical Crystallization Summit gathers leading industrial and academic experts to discuss their works related to DS crystallization R&D and manufacturing focuses on:
Areas of opportunity identified by Enabling Technologies Consortium (ETC)
Areas of potential innovation identified by National Academies of Sciences, Engineering, and Medicine (NASEM)
This year’s summit will be proceeding as a hybrid (live and virtual) event in 2 days with 12 keynote presentations and 3 topical panel discussions, moderated by SMEs from the pharma industry, covering the following topical sessions:
“Serving the patients with the right DP in the fastest way possible requires scientists on the DS side, and DP side to work hand in hand, not in isolation. The speakers at this conference will demonstrate how this kind of collaboration can lead to experimental and theoretical tools to better understand the fundamentals of APIs, their interaction with excipients, API crystallization and formulation processes,” said Dr. San Kiang, CTO of Porton, Chairman of the Pharmaceutical Crystallization Summit.